Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection
Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept c...
Saved in:
| Published in: | EBioMedicine Vol. 66; p. 103310 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier B.V
01.04.2021
Elsevier |
| Subjects: | |
| ISSN: | 2352-3964, 2352-3964 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis.
In this randomized, double blind, placebo-controlled trial, healthy adults were randomized 1:1 to receive Flexyn2a (10 µg) or placebo intramuscularly, twice, 4 weeks apart, followed by challenge 4 weeks later with 1500 colony forming units (CFUs) of S. flexneri 2a strain 2457T. The primary outcome was vaccine-induced protection. S. flexneri 2a lipopolysaccharide (LPS)-specific immune responses were assessed.
Sixty-seven subjects were enrolled, 34 received vaccine and 33 placebo. The vaccine was well tolerated; the majority of adverse events were mild in nature. Thirty vaccinees and 29 placebo recipients received the S. flexneri 2a challenge. Vaccination resulted in a 30.2% reduction in shigellosis compared with placebo (13/30 vs. 18/29; p = 0.11; 95% CI -15 to 62.6). Vaccine efficacy was more robust against severe disease, reaching 51.7% (p = 0.015, 95% CI 5.3 to 77.9) against moderate/severe diarrhoea or dysentery concurrent with fever or severe enteric symptoms and 72.4% (p = 0.07) against more severe diarrhoea (≥10 lose stools or ≥1000 g loose stools/24 h). Vaccinated subjects were less likely to need early antibiotic intervention following challenge (protective efficacy 51.7%, p = 0.01; 95% CI 9 to 76.8). In those who developed shigellosis, vaccinated subjects had a lower disease severity score (p = 0.002) than placebo-recipients. Additionally, LPS-specific serum IgG responses in Flexyn2a recipients were associated with protection against disease (p = 0.0016) and with a decreased shigellosis disease score (p = 0.002).
The Flexyn2a bioconjugate vaccine was immunogenic, well tolerated and protected against severe illness after Shigella challenge and is a promising Shigella vaccine construct. We identified a strong association between anti-S. flexneri 2a serum IgG and a reduction in disease outcomes. (Clinicaltrials.gov, NCT02646371.)
Funding for this study was through a grant from the Wellcome Trust. |
|---|---|
| AbstractList | Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis.BACKGROUNDShigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis.In this randomized, double blind, placebo-controlled trial, healthy adults were randomized 1:1 to receive Flexyn2a (10 µg) or placebo intramuscularly, twice, 4 weeks apart, followed by challenge 4 weeks later with 1500 colony forming units (CFUs) of S. flexneri 2a strain 2457T. The primary outcome was vaccine-induced protection. S. flexneri 2a lipopolysaccharide (LPS)-specific immune responses were assessed.METHODSIn this randomized, double blind, placebo-controlled trial, healthy adults were randomized 1:1 to receive Flexyn2a (10 µg) or placebo intramuscularly, twice, 4 weeks apart, followed by challenge 4 weeks later with 1500 colony forming units (CFUs) of S. flexneri 2a strain 2457T. The primary outcome was vaccine-induced protection. S. flexneri 2a lipopolysaccharide (LPS)-specific immune responses were assessed.Sixty-seven subjects were enrolled, 34 received vaccine and 33 placebo. The vaccine was well tolerated; the majority of adverse events were mild in nature. Thirty vaccinees and 29 placebo recipients received the S. flexneri 2a challenge. Vaccination resulted in a 30.2% reduction in shigellosis compared with placebo (13/30 vs. 18/29; p = 0.11; 95% CI -15 to 62.6). Vaccine efficacy was more robust against severe disease, reaching 51.7% (p = 0.015, 95% CI 5.3 to 77.9) against moderate/severe diarrhoea or dysentery concurrent with fever or severe enteric symptoms and 72.4% (p = 0.07) against more severe diarrhoea (≥10 lose stools or ≥1000 g loose stools/24 h). Vaccinated subjects were less likely to need early antibiotic intervention following challenge (protective efficacy 51.7%, p = 0.01; 95% CI 9 to 76.8). In those who developed shigellosis, vaccinated subjects had a lower disease severity score (p = 0.002) than placebo-recipients. Additionally, LPS-specific serum IgG responses in Flexyn2a recipients were associated with protection against disease (p = 0.0016) and with a decreased shigellosis disease score (p = 0.002).FINDINGSSixty-seven subjects were enrolled, 34 received vaccine and 33 placebo. The vaccine was well tolerated; the majority of adverse events were mild in nature. Thirty vaccinees and 29 placebo recipients received the S. flexneri 2a challenge. Vaccination resulted in a 30.2% reduction in shigellosis compared with placebo (13/30 vs. 18/29; p = 0.11; 95% CI -15 to 62.6). Vaccine efficacy was more robust against severe disease, reaching 51.7% (p = 0.015, 95% CI 5.3 to 77.9) against moderate/severe diarrhoea or dysentery concurrent with fever or severe enteric symptoms and 72.4% (p = 0.07) against more severe diarrhoea (≥10 lose stools or ≥1000 g loose stools/24 h). Vaccinated subjects were less likely to need early antibiotic intervention following challenge (protective efficacy 51.7%, p = 0.01; 95% CI 9 to 76.8). In those who developed shigellosis, vaccinated subjects had a lower disease severity score (p = 0.002) than placebo-recipients. Additionally, LPS-specific serum IgG responses in Flexyn2a recipients were associated with protection against disease (p = 0.0016) and with a decreased shigellosis disease score (p = 0.002).The Flexyn2a bioconjugate vaccine was immunogenic, well tolerated and protected against severe illness after Shigella challenge and is a promising Shigella vaccine construct. We identified a strong association between anti-S. flexneri 2a serum IgG and a reduction in disease outcomes. (Clinicaltrials.gov, NCT02646371.) FUNDING: Funding for this study was through a grant from the Wellcome Trust.INTERPRETATIONThe Flexyn2a bioconjugate vaccine was immunogenic, well tolerated and protected against severe illness after Shigella challenge and is a promising Shigella vaccine construct. We identified a strong association between anti-S. flexneri 2a serum IgG and a reduction in disease outcomes. (Clinicaltrials.gov, NCT02646371.) FUNDING: Funding for this study was through a grant from the Wellcome Trust. Background: Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis. Methods: In this randomized, double blind, placebo-controlled trial, healthy adults were randomized 1:1 to receive Flexyn2a (10 µg) or placebo intramuscularly, twice, 4 weeks apart, followed by challenge 4 weeks later with 1500 colony forming units (CFUs) of S. flexneri 2a strain 2457T. The primary outcome was vaccine-induced protection. S. flexneri 2a lipopolysaccharide (LPS)-specific immune responses were assessed. Findings: Sixty-seven subjects were enrolled, 34 received vaccine and 33 placebo. The vaccine was well tolerated; the majority of adverse events were mild in nature. Thirty vaccinees and 29 placebo recipients received the S. flexneri 2a challenge. Vaccination resulted in a 30.2% reduction in shigellosis compared with placebo (13/30 vs. 18/29; p = 0.11; 95% CI -15 to 62.6). Vaccine efficacy was more robust against severe disease, reaching 51.7% (p = 0.015, 95% CI 5.3 to 77.9) against moderate/severe diarrhoea or dysentery concurrent with fever or severe enteric symptoms and 72.4% (p = 0.07) against more severe diarrhoea (≥10 lose stools or ≥1000 g loose stools/24 h). Vaccinated subjects were less likely to need early antibiotic intervention following challenge (protective efficacy 51.7%, p = 0.01; 95% CI 9 to 76.8). In those who developed shigellosis, vaccinated subjects had a lower disease severity score (p = 0.002) than placebo-recipients. Additionally, LPS-specific serum IgG responses in Flexyn2a recipients were associated with protection against disease (p = 0.0016) and with a decreased shigellosis disease score (p = 0.002). Interpretation: The Flexyn2a bioconjugate vaccine was immunogenic, well tolerated and protected against severe illness after Shigella challenge and is a promising Shigella vaccine construct. We identified a strong association between anti-S. flexneri 2a serum IgG and a reduction in disease outcomes. (Clinicaltrials.gov, NCT02646371.) Funding: Funding for this study was through a grant from the Wellcome Trust. Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis. In this randomized, double blind, placebo-controlled trial, healthy adults were randomized 1:1 to receive Flexyn2a (10 µg) or placebo intramuscularly, twice, 4 weeks apart, followed by challenge 4 weeks later with 1500 colony forming units (CFUs) of S. flexneri 2a strain 2457T. The primary outcome was vaccine-induced protection. S. flexneri 2a lipopolysaccharide (LPS)-specific immune responses were assessed. Sixty-seven subjects were enrolled, 34 received vaccine and 33 placebo. The vaccine was well tolerated; the majority of adverse events were mild in nature. Thirty vaccinees and 29 placebo recipients received the S. flexneri 2a challenge. Vaccination resulted in a 30.2% reduction in shigellosis compared with placebo (13/30 vs. 18/29; p = 0.11; 95% CI -15 to 62.6). Vaccine efficacy was more robust against severe disease, reaching 51.7% (p = 0.015, 95% CI 5.3 to 77.9) against moderate/severe diarrhoea or dysentery concurrent with fever or severe enteric symptoms and 72.4% (p = 0.07) against more severe diarrhoea (≥10 lose stools or ≥1000 g loose stools/24 h). Vaccinated subjects were less likely to need early antibiotic intervention following challenge (protective efficacy 51.7%, p = 0.01; 95% CI 9 to 76.8). In those who developed shigellosis, vaccinated subjects had a lower disease severity score (p = 0.002) than placebo-recipients. Additionally, LPS-specific serum IgG responses in Flexyn2a recipients were associated with protection against disease (p = 0.0016) and with a decreased shigellosis disease score (p = 0.002). The Flexyn2a bioconjugate vaccine was immunogenic, well tolerated and protected against severe illness after Shigella challenge and is a promising Shigella vaccine construct. We identified a strong association between anti-S. flexneri 2a serum IgG and a reduction in disease outcomes. (Clinicaltrials.gov, NCT02646371.) FUNDING: Funding for this study was through a grant from the Wellcome Trust. AbstractBackgroundShigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis. MethodsIn this randomized, double blind, placebo-controlled trial, healthy adults were randomized 1:1 to receive Flexyn2a (10 µg) or placebo intramuscularly, twice, 4 weeks apart, followed by challenge 4 weeks later with 1500 colony forming units (CFUs) of S. flexneri 2a strain 2457T. The primary outcome was vaccine-induced protection. S. flexneri 2a lipopolysaccharide (LPS)-specific immune responses were assessed. FindingsSixty-seven subjects were enrolled, 34 received vaccine and 33 placebo. The vaccine was well tolerated; the majority of adverse events were mild in nature. Thirty vaccinees and 29 placebo recipients received the S. flexneri 2a challenge. Vaccination resulted in a 30.2% reduction in shigellosis compared with placebo (13/30 vs. 18/29; p = 0.11; 95% CI -15 to 62.6). Vaccine efficacy was more robust against severe disease, reaching 51.7% ( p = 0.015, 95% CI 5.3 to 77.9) against moderate/severe diarrhoea or dysentery concurrent with fever or severe enteric symptoms and 72.4% ( p = 0.07) against more severe diarrhoea (≥10 lose stools or ≥1000 g loose stools/24 h). Vaccinated subjects were less likely to need early antibiotic intervention following challenge (protective efficacy 51.7%, p = 0.01; 95% CI 9 to 76.8). In those who developed shigellosis, vaccinated subjects had a lower disease severity score ( p = 0.002) than placebo-recipients. Additionally, LPS-specific serum IgG responses in Flexyn2a recipients were associated with protection against disease ( p = 0.0016) and with a decreased shigellosis disease score ( p = 0.002). InterpretationThe Flexyn2a bioconjugate vaccine was immunogenic, well tolerated and protected against severe illness after Shigella challenge and is a promising Shigella vaccine construct. We identified a strong association between anti- S. flexneri 2a serum IgG and a reduction in disease outcomes. (Clinicaltrials.gov, NCT02646371.) FundingFunding for this study was through a grant from the Wellcome Trust. Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a vaccine conjugates the O-polysaccharide of Shigella flexneri 2a to Pseudomonas aeruginosa exotoxin A. We describe a Phase 2b proof-of-concept challenge study that evaluated safety, immunogenicity, and efficacy of the Flexyn2a vaccine to protect against shigellosis. In this randomized, double blind, placebo-controlled trial, healthy adults were randomized 1:1 to receive Flexyn2a (10 µg) or placebo intramuscularly, twice, 4 weeks apart, followed by challenge 4 weeks later with 1500 colony forming units (CFUs) of S. flexneri 2a strain 2457T. The primary outcome was vaccine-induced protection. S. flexneri 2a lipopolysaccharide (LPS)-specific immune responses were assessed. Sixty-seven subjects were enrolled, 34 received vaccine and 33 placebo. The vaccine was well tolerated; the majority of adverse events were mild in nature. Thirty vaccinees and 29 placebo recipients received the S. flexneri 2a challenge. Vaccination resulted in a 30.2% reduction in shigellosis compared with placebo (13/30 vs. 18/29; p = 0.11; 95% CI -15 to 62.6). Vaccine efficacy was more robust against severe disease, reaching 51.7% (p = 0.015, 95% CI 5.3 to 77.9) against moderate/severe diarrhoea or dysentery concurrent with fever or severe enteric symptoms and 72.4% (p = 0.07) against more severe diarrhoea (≥10 lose stools or ≥1000 g loose stools/24 h). Vaccinated subjects were less likely to need early antibiotic intervention following challenge (protective efficacy 51.7%, p = 0.01; 95% CI 9 to 76.8). In those who developed shigellosis, vaccinated subjects had a lower disease severity score (p = 0.002) than placebo-recipients. Additionally, LPS-specific serum IgG responses in Flexyn2a recipients were associated with protection against disease (p = 0.0016) and with a decreased shigellosis disease score (p = 0.002). The Flexyn2a bioconjugate vaccine was immunogenic, well tolerated and protected against severe illness after Shigella challenge and is a promising Shigella vaccine construct. We identified a strong association between anti-S. flexneri 2a serum IgG and a reduction in disease outcomes. (Clinicaltrials.gov, NCT02646371.) Funding for this study was through a grant from the Wellcome Trust. |
| ArticleNumber | 103310 |
| Author | Alaimo, Cristina DeNearing, Barbara Bourgeois, A. Louis Riddle, Mark S. Chakraborty, Subhra Dreyer, Anita M. Martin, Patricia Kaminski, Robert W. Clarkson, Kristen A. Elwood, Daniel Sack, David Porter, Chad K. Halpern, Jane Fonck, Veronica Gambillara Brubaker, Jessica Talaat, Kawsar R. Weerts, Hailey Feijoo, Brittany L. Frölich, Rahel |
| Author_xml | – sequence: 1 givenname: Kawsar R. orcidid: 0000-0002-4899-6260 surname: Talaat fullname: Talaat, Kawsar R. email: ktalaat@jhu.edu organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 2 givenname: Cristina surname: Alaimo fullname: Alaimo, Cristina organization: LimmaTech Biologics AG, Schlieren, Switzerland – sequence: 3 givenname: Patricia surname: Martin fullname: Martin, Patricia organization: LimmaTech Biologics AG, Schlieren, Switzerland – sequence: 4 givenname: A. Louis surname: Bourgeois fullname: Bourgeois, A. Louis organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 5 givenname: Anita M. surname: Dreyer fullname: Dreyer, Anita M. organization: LimmaTech Biologics AG, Schlieren, Switzerland – sequence: 6 givenname: Robert W. surname: Kaminski fullname: Kaminski, Robert W. organization: Walter Reed Army Institute of Research, Silver Spring, MD, United States – sequence: 7 givenname: Chad K. surname: Porter fullname: Porter, Chad K. organization: Naval Medical Research Center, Silver Spring, MD, United States – sequence: 8 givenname: Subhra surname: Chakraborty fullname: Chakraborty, Subhra organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 9 givenname: Kristen A. surname: Clarkson fullname: Clarkson, Kristen A. organization: Walter Reed Army Institute of Research, Silver Spring, MD, United States – sequence: 10 givenname: Jessica surname: Brubaker fullname: Brubaker, Jessica organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 11 givenname: Daniel surname: Elwood fullname: Elwood, Daniel organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 12 givenname: Rahel surname: Frölich fullname: Frölich, Rahel organization: LimmaTech Biologics AG, Schlieren, Switzerland – sequence: 13 givenname: Barbara surname: DeNearing fullname: DeNearing, Barbara organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 14 givenname: Hailey surname: Weerts fullname: Weerts, Hailey organization: Walter Reed Army Institute of Research, Silver Spring, MD, United States – sequence: 15 givenname: Brittany L. orcidid: 0000-0002-7566-5870 surname: Feijoo fullname: Feijoo, Brittany L. organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 16 givenname: Jane surname: Halpern fullname: Halpern, Jane organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 17 givenname: David surname: Sack fullname: Sack, David organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States – sequence: 18 givenname: Mark S. surname: Riddle fullname: Riddle, Mark S. organization: Naval Medical Research Center, Silver Spring, MD, United States – sequence: 19 givenname: Veronica Gambillara surname: Fonck fullname: Fonck, Veronica Gambillara organization: LimmaTech Biologics AG, Schlieren, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33862589$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1rFDEUHaRia-0vECSPvuyaj8l8KBZKUVso-FB9Dsmdm92ss0lNZrbsvzfTbUtbkH264eacc5N7ztviwAePRfGe0TmjrPq0mqNxYT3nlLPcEYLRV8URF5LPRFuVB0_Oh8VJSitKKZNlbjZvikMhmorLpj0qxotxrT2Bpe579AskaRi7Lbl1w5Jocr10C-x7TfIsCH41LvSAZKMBnMfP5MzrfpswkWAJ9M470D1Ba3OFLdG-IxBixH4iZchNDAPC4IJ_V7y2uk94cl-Pi9_fv_06v5hd_fxxeX52NYNK8GFWW45NWbdgKlszzgwAmNoaY5g1NTcIrcVa1pK2FhqTP1zLLn-xLi1rS9qK4-Jyp9sFvVI30a113KqgnbprhLhQOg4OelSsZNSKmou8pxJAGAOcSW2ksIZL2WSt053WzWjW2AH6Ier-mejzG--WahE2qqGyZLLOAh_vBWL4O2Ia1NolmNbrMYxJccnKioq6khn64emsxyEPvmWA2AEghpQi2kcIo2oKiFqpu4CoKSBqF5DMal-wwA16MiQ_2PV7uF93XMx-bRxGlcChB-xczKbmhbo9_NMX_IfE_MEtplUYY05TUkwlrqi6nuI7pZezbAgVLAt8-b_A3vH_ALOrAR4 |
| CitedBy_id | crossref_primary_10_3390_vaccines10020212 crossref_primary_10_12688_wellcomeopenres_19012_1 crossref_primary_10_36233_0372_9311_696 crossref_primary_10_1371_journal_pone_0290987 crossref_primary_10_1093_cid_ciad022 crossref_primary_10_3390_vaccines10091376 crossref_primary_10_1093_infdis_jiab462 crossref_primary_10_3390_vaccines10040548 crossref_primary_10_1038_s41541_025_01064_6 crossref_primary_10_1371_journal_pntd_0010180 crossref_primary_10_1016_j_vaccine_2023_06_052 crossref_primary_10_1128_msphere_01020_21 crossref_primary_10_3390_ijms24054649 crossref_primary_10_3390_vaccines11020333 crossref_primary_10_1002_bit_28876 crossref_primary_10_1016_j_cmi_2022_10_011 crossref_primary_10_3389_fcimb_2023_1171213 crossref_primary_10_1128_cmr_00075_23 crossref_primary_10_3390_microorganisms12020288 crossref_primary_10_1038_s41564_021_01054_z crossref_primary_10_1016_j_coi_2022_102235 crossref_primary_10_1016_j_micpath_2023_106066 crossref_primary_10_3389_fimmu_2022_971866 crossref_primary_10_1016_S1473_3099_23_00294_3 crossref_primary_10_1016_S0140_6736_25_01033_5 crossref_primary_10_3390_ijms25105487 crossref_primary_10_3390_vaccines10050645 crossref_primary_10_1038_s41541_023_00797_6 crossref_primary_10_3389_fimmu_2023_1290414 crossref_primary_10_1128_mSphere_00122_21 crossref_primary_10_3389_fmicb_2022_983403 crossref_primary_10_3390_vaccines10010033 crossref_primary_10_1016_j_ijid_2023_01_034 crossref_primary_10_1038_s41541_023_00624_y crossref_primary_10_1080_14760584_2023_2274955 crossref_primary_10_1021_acscentsci_1c01479 crossref_primary_10_3390_vaccines10040489 crossref_primary_10_1128_msphere_00019_23 crossref_primary_10_1093_ofid_ofad041 crossref_primary_10_3390_vaccines10020328 crossref_primary_10_3390_vaccines10050675 crossref_primary_10_1097_MOP_0000000000001107 crossref_primary_10_12688_wellcomeopenres_17869_1 crossref_primary_10_1128_mmbr_00045_22 crossref_primary_10_1097_QCO_0000000000000758 crossref_primary_10_3389_fmed_2025_1578560 crossref_primary_10_3390_vaccines12101091 crossref_primary_10_3389_fimmu_2024_1483740 crossref_primary_10_1016_j_vaccine_2023_08_051 crossref_primary_10_1016_j_vaccine_2022_12_037 crossref_primary_10_1136_bmjopen_2021_058740 crossref_primary_10_12688_wellcomeopenres_19012_2 crossref_primary_10_3390_pathogens10111353 crossref_primary_10_3390_vaccines10020282 crossref_primary_10_1186_s13643_025_02856_6 |
| Cites_doi | 10.1097/INF.0000000000000351 10.1093/cid/ciz891 10.1016/S2214-109X(18)30483-2 10.1016/j.vaccine.2009.12.050 10.1371/journal.pone.0046916 10.1128/CVI.00224-16 10.1093/infdis/125.1.12 10.1016/0264-410X(90)90094-3 10.1542/peds.73.6.799 10.1016/S1473-3099(17)30108-1 10.1017/S0950268812001677 10.1093/cid/ciz892 10.1016/j.vaccine.2008.10.081 10.1016/S2214-109X(18)30351-6 10.1016/S0140-6736(16)31529-X 10.1093/cid/ciz909 10.2307/4586560 10.1128/IAI.68.12.6624-6632.2000 10.1086/503039 10.1016/0264-410X(95)00102-7 10.1016/S0140-6736(96)06255-1 10.1128/jcm.29.2.386-389.1991 10.1093/infdis/165.4.785 10.1016/S2214-109X(15)00151-5 10.1016/j.vaccine.2015.06.102 10.1080/21645515.2018.1474316 10.1016/S0140-6736(17)33296-8 10.1371/journal.pone.0194325 10.1086/516452 10.2307/2527727 10.1093/infdis/jiw359 10.1016/j.idc.2019.05.007 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors The Authors Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. 2021 The Authors 2021 |
| Copyright_xml | – notice: 2021 The Authors – notice: The Authors – notice: Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. – notice: 2021 The Authors 2021 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ebiom.2021.103310 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2352-3964 |
| EndPage | 103310 |
| ExternalDocumentID | oai_doaj_org_article_1410f37230014cc3bbc215ab53fb2558 PMC8054157 33862589 10_1016_j_ebiom_2021_103310 S2352396421001031 1_s2_0_S2352396421001031 |
| Genre | Journal Article |
| GroupedDBID | .1- .FO 0R~ 4.4 457 53G 5VS AAEDT AAEDW AAIKJ AALRI AAMRU AAXUO AAYWO ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADRAZ ADVLN AEUPX AEXQZ AFPUW AFRHN AFTJW AGHFR AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS EJD FDB GROUPED_DOAJ HYE HZ~ IPNFZ KQ8 M41 M48 O9- OK1 RIG ROL RPM SSZ Z5R 0SF 6I. AACTN AAFTH AFCTW NCXOZ AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c632t-7f2e8479cb6f7121bcccb7fbbb1fb72bec9fe757509fc8b35275d23574f194093 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 59 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000647447600023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2352-3964 |
| IngestDate | Fri Oct 03 12:34:56 EDT 2025 Tue Nov 04 01:59:54 EST 2025 Sun Nov 09 11:55:23 EST 2025 Thu Apr 03 07:08:09 EDT 2025 Tue Nov 18 21:48:56 EST 2025 Thu Nov 13 04:36:07 EST 2025 Tue Jul 25 21:01:30 EDT 2023 Sun Feb 23 10:19:25 EST 2025 Tue Aug 26 16:33:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Controlled human challenge study Vaccine Shigella flexneri 2a Bioconjugate vaccine Shigella |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c632t-7f2e8479cb6f7121bcccb7fbbb1fb72bec9fe757509fc8b35275d23574f194093 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 These authors Contributed equally to this work |
| ORCID | 0000-0002-4899-6260 0000-0002-7566-5870 |
| OpenAccessLink | https://doaj.org/article/1410f37230014cc3bbc215ab53fb2558 |
| PMID | 33862589 |
| PQID | 2514603765 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1410f37230014cc3bbc215ab53fb2558 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8054157 proquest_miscellaneous_2514603765 pubmed_primary_33862589 crossref_primary_10_1016_j_ebiom_2021_103310 crossref_citationtrail_10_1016_j_ebiom_2021_103310 elsevier_sciencedirect_doi_10_1016_j_ebiom_2021_103310 elsevier_clinicalkeyesjournals_1_s2_0_S2352396421001031 elsevier_clinicalkey_doi_10_1016_j_ebiom_2021_103310 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-01 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | EBioMedicine |
| PublicationTitleAlternate | EBioMedicine |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Simon, Wahid, Maciel (bib0034) 2009; 27 Rodenburg, Sanders, van Gils (bib0027) 2012; 7 Cohen, Ashkenazi, Green (bib0011) 1997; 349 Porter, Thura, Ranallo, Riddle (bib0018) 2013; 141 Hardy, Decapito, Halbert (bib0009) 1948; 63 Hatz, Bally, Rohrer (bib0013) 2015; 33 Huttner, Hatz, van den Dobbelsteen (bib0014) 2017; 17 Rogawski, Liu, Platts-Mills (bib0007) 2018; 6 Talaat, Bourgeois, Frenck (bib0020) 2019; 69 DuPont, Hornick, Snyder, Libonati, Formal, Gangarosa (bib0029) 1972; 125 Robin, Cohen, Orr (bib0033) 1997; 175 MacLennan, Riddle, Chen (bib0022) 2019; 69 Bross (bib0025) 1958; 14 Platts-Mills, Babji, Bodhidatta (bib0003) 2015; 3 Taylor, McKenzie, Durbin (bib0019) 2006; 42 Pinto, Kemp, Torres (bib0026) 2016; 214 Vincent (bib0010) 1921; 29 Inoue, Ogawa, Tamura (bib0016) 2018; 14 Lee, Paredes Olortegui, Yori (bib0005) 2014; 33 Shakoor, Platts-Mills, Hasan (bib0008) 2019; 33 Herrington, Van de Verg, Formal (bib0030) 1990; 8 Anderson, Bagamian, Muhib (bib0006) 2019; 7 Black, Brown, Becker (bib0004) 1984; 73 Kotloff, Nataro, Losonsky (bib0028) 1995; 13 Cohen, Green, Block, Slepon, Lerman (bib0031) 1992; 165 Cohen, Green, Block, Slepon, Ofek (bib0032) 1991; 29 Liu, Platts-Mills, Juma (bib0002) 2016; 388 Turbyfill, Hartman, Oaks (bib0024) 2000; 68 Kotloff, Riddle, Platts-Mills, Pavlinac, Zaidi (bib0001) 2018; 391 Ravenscroft, Haeuptle, Kowarik (bib0017) 2016; 26 Porter, Lynen, Riddle (bib0023) 2018; 13 Passwell, Ashkenzi, Banet-Levi (bib0012) 2010; 28 Riddle, Kaminski, Di Paolo (bib0015) 2016; 23 Kaminski, Pasetti, Aguilar (bib0021) 2019; 69 Black (10.1016/j.ebiom.2021.103310_bib0004) 1984; 73 Passwell (10.1016/j.ebiom.2021.103310_bib0012) 2010; 28 Porter (10.1016/j.ebiom.2021.103310_bib0023) 2018; 13 Platts-Mills (10.1016/j.ebiom.2021.103310_bib0003) 2015; 3 Turbyfill (10.1016/j.ebiom.2021.103310_bib0024) 2000; 68 Hardy (10.1016/j.ebiom.2021.103310_bib0009) 1948; 63 Vincent (10.1016/j.ebiom.2021.103310_bib0010) 1921; 29 Lee (10.1016/j.ebiom.2021.103310_bib0005) 2014; 33 Inoue (10.1016/j.ebiom.2021.103310_bib0016) 2018; 14 Ravenscroft (10.1016/j.ebiom.2021.103310_bib0017) 2016; 26 Simon (10.1016/j.ebiom.2021.103310_bib0034) 2009; 27 Rogawski (10.1016/j.ebiom.2021.103310_bib0007) 2018; 6 Cohen (10.1016/j.ebiom.2021.103310_bib0032) 1991; 29 Cohen (10.1016/j.ebiom.2021.103310_bib0031) 1992; 165 Liu (10.1016/j.ebiom.2021.103310_bib0002) 2016; 388 Robin (10.1016/j.ebiom.2021.103310_bib0033) 1997; 175 Anderson (10.1016/j.ebiom.2021.103310_bib0006) 2019; 7 MacLennan (10.1016/j.ebiom.2021.103310_bib0022) 2019; 69 Kotloff (10.1016/j.ebiom.2021.103310_bib0001) 2018; 391 Riddle (10.1016/j.ebiom.2021.103310_bib0015) 2016; 23 Kotloff (10.1016/j.ebiom.2021.103310_bib0028) 1995; 13 Kaminski (10.1016/j.ebiom.2021.103310_bib0021) 2019; 69 Porter (10.1016/j.ebiom.2021.103310_bib0018) 2013; 141 Rodenburg (10.1016/j.ebiom.2021.103310_bib0027) 2012; 7 Hatz (10.1016/j.ebiom.2021.103310_bib0013) 2015; 33 DuPont (10.1016/j.ebiom.2021.103310_bib0029) 1972; 125 Shakoor (10.1016/j.ebiom.2021.103310_bib0008) 2019; 33 Cohen (10.1016/j.ebiom.2021.103310_bib0011) 1997; 349 Talaat (10.1016/j.ebiom.2021.103310_bib0020) 2019; 69 Bross (10.1016/j.ebiom.2021.103310_bib0025) 1958; 14 Pinto (10.1016/j.ebiom.2021.103310_bib0026) 2016; 214 Herrington (10.1016/j.ebiom.2021.103310_bib0030) 1990; 8 Huttner (10.1016/j.ebiom.2021.103310_bib0014) 2017; 17 Taylor (10.1016/j.ebiom.2021.103310_bib0019) 2006; 42 |
| References_xml | – volume: 73 start-page: 799 year: 1984 end-page: 805 ident: bib0004 article-title: Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh publication-title: Pediatrics – volume: 33 start-page: 1004 year: 2014 end-page: 1009 ident: bib0005 article-title: Effects of Shigella, campylobacter- and ETEC-associated diarrhea on childhood growth publication-title: Pediatr Infect Dis J – volume: 165 start-page: 785 year: 1992 end-page: 787 ident: bib0031 article-title: Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide publication-title: J Infect Dis – volume: 175 start-page: 1128 year: 1997 end-page: 1133 ident: bib0033 article-title: Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection publication-title: J Infect Dis – volume: 214 start-page: 1276 year: 2016 end-page: 1283 ident: bib0026 article-title: Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial publication-title: J Infect Dis – volume: 125 start-page: 12 year: 1972 end-page: 16 ident: bib0029 article-title: Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection publication-title: J Infect Dis – volume: 69 start-page: S580 year: 2019 end-page: SS90 ident: bib0020 article-title: Consensus report on Shigella controlled human infection model: conduct of studies publication-title: Clin Infect Dis – volume: 33 start-page: 4594 year: 2015 end-page: 4601 ident: bib0013 article-title: Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study publication-title: Vaccine – volume: 7 start-page: e46916 year: 2012 ident: bib0027 article-title: Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life publication-title: PLOS ONE – volume: 14 start-page: 2150 year: 2018 end-page: 2157 ident: bib0016 article-title: Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: a phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants publication-title: Hum Vaccin Immunother – volume: 6 start-page: e1319 year: 2018 end-page: e1e28 ident: bib0007 article-title: Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study publication-title: Lancet Glob Health – volume: 23 start-page: 908 year: 2016 end-page: 917 ident: bib0015 article-title: Safety and Immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study publication-title: Clin vaccin immunol CVI – volume: 13 year: 2018 ident: bib0023 article-title: Clinical endpoints in the controlled human challenge model for Shigella: a call for standardization and the development of a disease severity score publication-title: PLOS ONE – volume: 17 start-page: 528 year: 2017 end-page: 537 ident: bib0014 article-title: Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial publication-title: Lancet Infect Dis – volume: 68 start-page: 6624 year: 2000 end-page: 6632 ident: bib0024 article-title: Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine publication-title: Infect Immun – volume: 388 start-page: 1291 year: 2016 end-page: 1301 ident: bib0002 article-title: Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study publication-title: Lancet – volume: 27 start-page: 565 year: 2009 end-page: 572 ident: bib0034 article-title: Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates publication-title: Vaccine – volume: 8 start-page: 353 year: 1990 end-page: 357 ident: bib0030 article-title: Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease publication-title: Vaccine – volume: 13 start-page: 1488 year: 1995 end-page: 1494 ident: bib0028 article-title: A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity publication-title: Vaccine – volume: 29 start-page: 54 year: 1921 ident: bib0010 article-title: Vaccination against bacillary dysentery with ethero-vaccine publication-title: J of State Med – volume: 69 start-page: S596 year: 2019 end-page: S601 ident: bib0021 article-title: Consensus report on Shigella controlled human infection model: immunological assays publication-title: Clin Infect Dis – volume: 141 start-page: 223 year: 2013 end-page: 232 ident: bib0018 article-title: The Shigella human challenge model publication-title: Epidemiol Infect – volume: 14 start-page: 18 year: 1958 end-page: 38 ident: bib0025 article-title: How to use ridit analysis publication-title: Biometrics – volume: 3 start-page: e564 year: 2015 end-page: e575 ident: bib0003 article-title: Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED) publication-title: Lancet Glob Health – volume: 26 start-page: 51 year: 2016 end-page: 62 ident: bib0017 article-title: Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering escherichia coli publication-title: Glycobiology – volume: 7 start-page: e321 year: 2019 end-page: ee30 ident: bib0006 article-title: Burden of enterotoxigenic escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis publication-title: Lancet Glob Health – volume: 63 start-page: 685 year: 1948 end-page: 688 ident: bib0009 article-title: Studies of the acute diarrheal diseases; immunization in shigellosis publication-title: Public Health Rep – volume: 391 start-page: 801 year: 2018 end-page: 812 ident: bib0001 article-title: Shigellosis publication-title: Lancet – volume: 42 start-page: 1283 year: 2006 end-page: 1288 ident: bib0019 article-title: Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge publication-title: Clin infect dis off publ Infect Dis Soc Am – volume: 349 start-page: 155 year: 1997 end-page: 159 ident: bib0011 article-title: Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults publication-title: Lancet – volume: 28 start-page: 2231 year: 2010 end-page: 2235 ident: bib0012 article-title: Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children publication-title: Vaccine – volume: 69 start-page: S591 year: 2019 end-page: S5S5 ident: bib0022 article-title: Consensus report on Shigella controlled human infection model: clinical endpoints publication-title: Clin Infect Dis – volume: 33 start-page: 1105 year: 2019 end-page: 1123 ident: bib0008 article-title: Antibiotic-resistant enteric infections publication-title: Infect Dis Clin North Am – volume: 29 start-page: 386 year: 1991 end-page: 389 ident: bib0032 article-title: Prospective study of the association between serum antibodies to lipopolysaccharide publication-title: J Clin Microbiol – volume: 33 start-page: 1004 issue: 10 year: 2014 ident: 10.1016/j.ebiom.2021.103310_bib0005 article-title: Effects of Shigella, campylobacter- and ETEC-associated diarrhea on childhood growth publication-title: Pediatr Infect Dis J doi: 10.1097/INF.0000000000000351 – volume: 69 start-page: S591 issue: Supplement_8 year: 2019 ident: 10.1016/j.ebiom.2021.103310_bib0022 article-title: Consensus report on Shigella controlled human infection model: clinical endpoints publication-title: Clin Infect Dis doi: 10.1093/cid/ciz891 – volume: 7 start-page: e321 issue: 3 year: 2019 ident: 10.1016/j.ebiom.2021.103310_bib0006 article-title: Burden of enterotoxigenic escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(18)30483-2 – volume: 28 start-page: 2231 issue: 10 year: 2010 ident: 10.1016/j.ebiom.2021.103310_bib0012 article-title: Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children publication-title: Vaccine doi: 10.1016/j.vaccine.2009.12.050 – volume: 7 start-page: e46916 issue: 10 year: 2012 ident: 10.1016/j.ebiom.2021.103310_bib0027 article-title: Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life publication-title: PLOS ONE doi: 10.1371/journal.pone.0046916 – volume: 23 start-page: 908 issue: 12 year: 2016 ident: 10.1016/j.ebiom.2021.103310_bib0015 article-title: Safety and Immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study publication-title: Clin vaccin immunol CVI doi: 10.1128/CVI.00224-16 – volume: 125 start-page: 12 issue: 1 year: 1972 ident: 10.1016/j.ebiom.2021.103310_bib0029 article-title: Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection publication-title: J Infect Dis doi: 10.1093/infdis/125.1.12 – volume: 8 start-page: 353 issue: 4 year: 1990 ident: 10.1016/j.ebiom.2021.103310_bib0030 article-title: Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease publication-title: Vaccine doi: 10.1016/0264-410X(90)90094-3 – volume: 73 start-page: 799 issue: 6 year: 1984 ident: 10.1016/j.ebiom.2021.103310_bib0004 article-title: Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh publication-title: Pediatrics doi: 10.1542/peds.73.6.799 – volume: 17 start-page: 528 issue: 5 year: 2017 ident: 10.1016/j.ebiom.2021.103310_bib0014 article-title: Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30108-1 – volume: 141 start-page: 223 issue: 2 year: 2013 ident: 10.1016/j.ebiom.2021.103310_bib0018 article-title: The Shigella human challenge model publication-title: Epidemiol Infect doi: 10.1017/S0950268812001677 – volume: 69 start-page: S580 issue: Supplement_8 year: 2019 ident: 10.1016/j.ebiom.2021.103310_bib0020 article-title: Consensus report on Shigella controlled human infection model: conduct of studies publication-title: Clin Infect Dis doi: 10.1093/cid/ciz892 – volume: 27 start-page: 565 issue: 4 year: 2009 ident: 10.1016/j.ebiom.2021.103310_bib0034 article-title: Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates publication-title: Vaccine doi: 10.1016/j.vaccine.2008.10.081 – volume: 6 start-page: e1319 issue: 12 year: 2018 ident: 10.1016/j.ebiom.2021.103310_bib0007 article-title: Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(18)30351-6 – volume: 388 start-page: 1291 issue: 10051 year: 2016 ident: 10.1016/j.ebiom.2021.103310_bib0002 article-title: Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study publication-title: Lancet doi: 10.1016/S0140-6736(16)31529-X – volume: 69 start-page: S596 issue: Supplement_8 year: 2019 ident: 10.1016/j.ebiom.2021.103310_bib0021 article-title: Consensus report on Shigella controlled human infection model: immunological assays publication-title: Clin Infect Dis doi: 10.1093/cid/ciz909 – volume: 29 start-page: 54 year: 1921 ident: 10.1016/j.ebiom.2021.103310_bib0010 article-title: Vaccination against bacillary dysentery with ethero-vaccine publication-title: J of State Med – volume: 63 start-page: 685 issue: 21 year: 1948 ident: 10.1016/j.ebiom.2021.103310_bib0009 article-title: Studies of the acute diarrheal diseases; immunization in shigellosis publication-title: Public Health Rep doi: 10.2307/4586560 – volume: 68 start-page: 6624 issue: 12 year: 2000 ident: 10.1016/j.ebiom.2021.103310_bib0024 article-title: Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine publication-title: Infect Immun doi: 10.1128/IAI.68.12.6624-6632.2000 – volume: 42 start-page: 1283 issue: 9 year: 2006 ident: 10.1016/j.ebiom.2021.103310_bib0019 article-title: Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge publication-title: Clin infect dis off publ Infect Dis Soc Am doi: 10.1086/503039 – volume: 13 start-page: 1488 issue: 16 year: 1995 ident: 10.1016/j.ebiom.2021.103310_bib0028 article-title: A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity publication-title: Vaccine doi: 10.1016/0264-410X(95)00102-7 – volume: 349 start-page: 155 issue: 9046 year: 1997 ident: 10.1016/j.ebiom.2021.103310_bib0011 article-title: Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults publication-title: Lancet doi: 10.1016/S0140-6736(96)06255-1 – volume: 29 start-page: 386 issue: 2 year: 1991 ident: 10.1016/j.ebiom.2021.103310_bib0032 article-title: Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis publication-title: J Clin Microbiol doi: 10.1128/jcm.29.2.386-389.1991 – volume: 165 start-page: 785 issue: 4 year: 1992 ident: 10.1016/j.ebiom.2021.103310_bib0031 article-title: Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide publication-title: J Infect Dis doi: 10.1093/infdis/165.4.785 – volume: 3 start-page: e564 issue: 9 year: 2015 ident: 10.1016/j.ebiom.2021.103310_bib0003 article-title: Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED) publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(15)00151-5 – volume: 33 start-page: 4594 issue: 36 year: 2015 ident: 10.1016/j.ebiom.2021.103310_bib0013 article-title: Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study publication-title: Vaccine doi: 10.1016/j.vaccine.2015.06.102 – volume: 14 start-page: 2150 issue: 9 year: 2018 ident: 10.1016/j.ebiom.2021.103310_bib0016 article-title: Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: a phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants publication-title: Hum Vaccin Immunother doi: 10.1080/21645515.2018.1474316 – volume: 391 start-page: 801 issue: 10122 year: 2018 ident: 10.1016/j.ebiom.2021.103310_bib0001 article-title: Shigellosis publication-title: Lancet doi: 10.1016/S0140-6736(17)33296-8 – volume: 13 issue: 3 year: 2018 ident: 10.1016/j.ebiom.2021.103310_bib0023 article-title: Clinical endpoints in the controlled human challenge model for Shigella: a call for standardization and the development of a disease severity score publication-title: PLOS ONE doi: 10.1371/journal.pone.0194325 – volume: 26 start-page: 51 issue: 1 year: 2016 ident: 10.1016/j.ebiom.2021.103310_bib0017 article-title: Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering escherichia coli publication-title: Glycobiology – volume: 175 start-page: 1128 issue: 5 year: 1997 ident: 10.1016/j.ebiom.2021.103310_bib0033 article-title: Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection publication-title: J Infect Dis doi: 10.1086/516452 – volume: 14 start-page: 18 issue: 1 year: 1958 ident: 10.1016/j.ebiom.2021.103310_bib0025 article-title: How to use ridit analysis publication-title: Biometrics doi: 10.2307/2527727 – volume: 214 start-page: 1276 issue: 8 year: 2016 ident: 10.1016/j.ebiom.2021.103310_bib0026 article-title: Quadrivalent human papillomavirus (HPV) vaccine induces HPV-specific antibodies in the oral cavity: results from the mid-adult male vaccine trial publication-title: J Infect Dis doi: 10.1093/infdis/jiw359 – volume: 33 start-page: 1105 issue: 4 year: 2019 ident: 10.1016/j.ebiom.2021.103310_bib0008 article-title: Antibiotic-resistant enteric infections publication-title: Infect Dis Clin North Am doi: 10.1016/j.idc.2019.05.007 |
| SSID | ssj0001542358 |
| Score | 2.4353387 |
| Snippet | Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The Flexyn2a... AbstractBackgroundShigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income... Background: Shigellosis is a major cause of moderate to severe diarrhoea and dysentery in children under 5 years of age in low and middle-income countries. The... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 103310 |
| SubjectTerms | Advanced Basic Science Bioconjugate vaccine Controlled human challenge study Internal Medicine Research Paper Shigella Shigella flexneri 2a Vaccine |
| Title | Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2352396421001031 https://www.clinicalkey.es/playcontent/1-s2.0-S2352396421001031 https://dx.doi.org/10.1016/j.ebiom.2021.103310 https://www.ncbi.nlm.nih.gov/pubmed/33862589 https://www.proquest.com/docview/2514603765 https://pubmed.ncbi.nlm.nih.gov/PMC8054157 https://doaj.org/article/1410f37230014cc3bbc215ab53fb2558 |
| Volume | 66 |
| WOSCitedRecordID | wos000647447600023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2352-3964 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001542358 issn: 2352-3964 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtaKGXkqYv9xFU6LGmq4ctq7e0NOQQQiEt7E1Ys1KzIXhDvBvIv--MZC-7bUkuudqSHzNjzTfyzDeMfdRKz6IypoxR6lK3AkprZVVGIPavBiYypkLhY3Ny0kyn9sdGqy_KCcv0wFlwnykPES-GSBnBPIDyHtBLtb5S0SMcTmW-E2M3gqlcH6ypBjR1lqtkqWytR8qhlNwVqLgdo0MpqOpcUf3shltK7P1b3ulf9Pl3EuWGVzrcZU8HOMkP8ms8Yw9Ct8ce5waTN8_ZKu3Rcxg7pvDEJstp85W3_PRs_puSnzg-JobF5yvaUuPXLdDP9i8885WEni8iHwsoeSDKiRZueNvNOFBrjwuahEMGxgfU8wv26_D7z29H5dBooYRayWVpogzopSz4OhohhQcAb6L3XkRvJKrZxmAqAhcRGo8SNdWMeHJ0FBYDRPWS7XSLLrxmHKMfBUaHKCMG3XKGaKeBxoDxqCsR64LJUc4OBhZyaoZx4cZ0s3OXlONIOS4rp2Cf1pMuMwnH7cO_kgLXQ4lBOx1Au3KDXbm77KpgelS_G2WMyypeaH77vc3_poV-WBp6J1wv3cSdkmGSXUqRe20UrF7PHNBPRjV33_LDaJ0O1wb64dN2YbHqHWJXXU_QhVQFe5WtdS0UpTCWrRqLD7xlx1tS2z7Tzc8S_3iDMF9U5s19iPkte0KvknOh3rGd5dUqvGeP4Ho576_22UMzbfbTp_0HmNlPoA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+challenge+study+with+a+Shigella+bioconjugate+vaccine%3A+Analyses+of+clinical+efficacy+and+correlate+of+protection&rft.jtitle=EBioMedicine&rft.au=Talaat%2C+Kawsar+R&rft.au=Alaimo%2C+Cristina&rft.au=Martin%2C+Patricia&rft.au=Bourgeois%2C+A.+Louis&rft.date=2021-04-01&rft.issn=2352-3964&rft.eissn=2352-3964&rft.volume=66&rft.spage=103310&rft.epage=103310&rft_id=info:doi/10.1016%2Fj.ebiom.2021.103310&rft.externalDBID=ECK1-s2.0-S2352396421001031&rft.externalDocID=1_s2_0_S2352396421001031 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F23523964%2FS2352396421X00047%2Fcov150h.gif |